Oncimmune publication further validates the ImmunoINSIGHTS Infectious Diseases panel

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication of a paper entitled: “Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection” 1 arising from the research collaboration between Oncimmune and Cedars-Sinai Medical Center in Los Angeles (“Cedars-Sinai”). The paper focuses on the sex-specific autoimmune reactivity to SARS-CoV-2 following mildly symptomatic infection as well as the prolonged effects of COVID-19 well beyond the initial infection and recovery phase.

This collaborative study focused on gaining an understanding of how COVID-19 infection affects a person’s immune system in ways that might persist over time. The research discovered that COVID-19 can trigger a broad autoantibody response that can last well beyond the initial infection and recovery phase, even among individuals who were only mildly affected or without any symptoms at all.

The research team used Oncimmune’s COVID-19 autoantibody profiling panel, an advanced panel of serological measures to understand which parts of the adaptive immune system are still activated for up to six months following full apparent recovery from the initial COVID-19 infection. The results showed that a wide array of autoantibodies remain elevated, including those linked to autoimmune conditions such as lupus and rheumatoid arthritis.

The study, published in the Journal of Translational Medicine, suggests that COVID-19 infection leads to a persistent activation of antibodies against multiple different organ systems and tissues, many of which have been linked to classic autoimmune diseases that typically affect women more than men. In this research, however, men were more affected than women. This latest study is the first to report both the presence of elevated autoantibodies after mild or asymptomatic infection and their persistence over time.

Dr Adam M Hill, CEO of Oncimmune said: “As the life science industry continues to work intensely to research and respond to the effects of COVID-19, and specifically to understand the immune system response to the disease, we are delighted to see this publication that further validates the ImmunoINSIGHTS Infectious Diseases panel and contributes to the knowledge base so that clinical outcomes from the disease can improve.”

1.   https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-03184-8

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    X
    LinkedIn

    More articles like this

    Fintel plc

    Fintel core revenue growth is higher than Zeus forecast

    Fintel plc (LON:FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has released a trading update for the six months to 30 June 2022, which reveals: Core revenue grew

    OnTheMarket Plc

    OnTheMarket analyst Zeus confident in forecasts

    Foxtons, one of London’s leading estate agencies with more than 50 interconnected branches across London, has signed an agreement to advertise its UK residential sales and letting properties at OnTheMarket plc (LON:OTMP). Zeus view: Foxtons, the

    SpaceandPeople analyst Zeus restores estimates and valuation

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued a

    Lookers Plc

    Lookers shares are still undervalued says Zeus

    Lookers plc (LON:LOOK) has released an H1 trading update reporting a continuation of strong performance year to date. H1 2022 underlying PBT is expected to be c. £45m and Management anticipate full year PBT will also

    Inchcape

    Inchcape performance exceeding expectations says Zeus

    Inchcape plc (LON:INCH) has released another positive trading update, with performance exceeding expectations so far this year. This follows on from a positive Q1 update on 28 April. Through quarterly improvement in Distribution volumes and operating

    boohoo Plc

    Boohoo Group analyst Zeus sees a strong performance in Q1

    ¨ Q1 financial highlights: Boohoo Group plc (LON:BOO) revenue of £445.7m is -8.3% YOY vs. a strong comp (Q1 FY22 revenue +32.1%), in line with Zeus’s forecast and management’s previously stated guidance. Gross sales growth remained